Log in

NASDAQ:GRTSGritstone Oncology Stock Price, Forecast & News

$6.73
+0.20 (+3.06 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.39
Now: $6.73
$6.88
50-Day Range
$6.27
MA: $6.80
$7.99
52-Week Range
$5.42
Now: $6.73
$12.96
Volume348,621 shs
Average Volume214,207 shs
Market Capitalization$250.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Read More
Gritstone Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRTS
CUSIPN/A
CIKN/A
Phone510-871-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.36 million
Book Value$3.75 per share

Profitability

Net Income$-94,430,000.00
Net Margins-2,397.90%

Miscellaneous

Employees113
Market Cap$250.76 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive GRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.

Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions

How has Gritstone Oncology's stock been impacted by COVID-19 (Coronavirus)?

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GRTS stock has increased by 0.9% and is now trading at $6.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gritstone Oncology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology.

When is Gritstone Oncology's next earnings date?

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Gritstone Oncology.

How were Gritstone Oncology's earnings last quarter?

Gritstone Oncology Inc (NASDAQ:GRTS) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The firm earned $1.26 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,397.90% and a negative return on equity of 69.76%. View Gritstone Oncology's earnings history.

What price target have analysts set for GRTS?

3 brokerages have issued twelve-month target prices for Gritstone Oncology's shares. Their forecasts range from $17.00 to $17.00. On average, they expect Gritstone Oncology's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 152.6% from the stock's current price. View analysts' price targets for Gritstone Oncology.

Has Gritstone Oncology been receiving favorable news coverage?

Media coverage about GRTS stock has trended extremely negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gritstone Oncology earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutGritstone Oncology.

Who are some of Gritstone Oncology's key competitors?

What other stocks do shareholders of Gritstone Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD) and Axsome Therapeutics (AXSM).

Who are Gritstone Oncology's key executives?

Gritstone Oncology's management team includes the following people:
  • Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)
  • Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)
  • Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)
  • Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)
  • Dr. Roman Yelensky, Exec. VP & CTO (Age 40)

When did Gritstone Oncology IPO?

(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone Oncology's stock symbol?

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone Oncology's major shareholders?

Gritstone Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.23%), Casdin Capital LLC (6.09%), BlackRock Inc. (5.88%), Victory Capital Management Inc. (0.95%), Victory Capital Management Inc. (0.94%) and Ensign Peak Advisors Inc (0.94%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View institutional ownership trends for Gritstone Oncology.

Which institutional investors are selling Gritstone Oncology stock?

GRTS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Ensign Peak Advisors Inc, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Gritstone Oncology.

Which institutional investors are buying Gritstone Oncology stock?

GRTS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Casdin Capital LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Nuveen Asset Management LLC, and Alliancebernstein L.P.. View insider buying and selling activity for Gritstone Oncology.

How do I buy shares of Gritstone Oncology?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gritstone Oncology's stock price today?

One share of GRTS stock can currently be purchased for approximately $6.73.

How big of a company is Gritstone Oncology?

Gritstone Oncology has a market capitalization of $250.76 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.

What is Gritstone Oncology's official website?

The official website for Gritstone Oncology is www.gritstoneoncology.com.

How can I contact Gritstone Oncology?

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at www.gritstoneoncology.com.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.